The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity), completed in 2023 with over 17,600 participants, demonstrated a 20% reduction in major adverse cardiovascular events in patients with established cardiovascular disease and overweight or obesity but without diabetes
Get a Quote MGF 5mg Mechano-growth factor alternative-splice variant of IGF-1 produced in response to mechanical loading
In a phase II study, gastrointestinal side effects were most common during semaglutide dose escalation but weight loss persisted beyond these events and continued through the 52-week trial period [51]
[5] Some patients with obesity may have mild elevations in cortisol or altered cortisol metabolism related to their weight status, and substantial weight loss could potentially normalise these patterns, though evidence for this specific effect is limited
Semaglutide has been on the market for some time and has shown clinically significant weight loss results, earning it FDA approval under the brand name Wegovy